News
LNTH
64.89
+0.05%
0.03
Weekly Report: what happened at LNTH last week (0126-0130)?
Weekly Report · 6d ago
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
Barchart · 01/31 21:41
Lantheus (LNTH) Receives a Buy from TD Cowen
TipRanks · 01/29 12:29
Weekly Report: what happened at LNTH last week (0119-0123)?
Weekly Report · 01/26 09:31
Weekly Report: what happened at LNTH last week (0112-0116)?
Weekly Report · 01/19 09:35
Lantheus: Management And Competition Raise Real Concern (Rating Downgrade)
Seeking Alpha · 01/16 07:19
Lantheus on Track for Lowest Close Since December 2025 -- Data Talk
Dow Jones · 01/15 17:57
Weekly Report: what happened at LNTH last week (0105-0109)?
Weekly Report · 01/12 09:34
3 Market-Beating Stocks for Long-Term Investors
Barchart · 01/12 06:00
Weekly Report: what happened at LNTH last week (1229-0102)?
Weekly Report · 01/05 09:32
Lantheus Closes Sale of SPECT Business to SHINE Technologies
Reuters · 01/02 13:00
Press Release: Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
Dow Jones · 01/02 13:00
Press Release: Lantheus Announces Closing of -2-
Dow Jones · 01/02 13:00
Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
Barchart · 01/02 07:00
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky
Barchart · 01/01 07:04
LANTHEUS HOLDINGS INC <LNTH.O>: TD COWEN RAISES TARGET PRICE TO $80 FROM $70
Reuters · 12/30/2025 16:31
TD Cowen Keeps Their Buy Rating on Lantheus (LNTH)
TipRanks · 12/30/2025 16:15
U.S. RESEARCH ROUNDUP-Citigroup, DigitalBridge, Verisk Analytics
Reuters · 12/30/2025 06:38
Weekly Report: what happened at LNTH last week (1222-1226)?
Weekly Report · 12/29/2025 09:31
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year
NASDAQ · 12/23/2025 23:45
More
Webull provides a variety of real-time LNTH stock news. You can receive the latest news about Lantheus Holding through multiple platforms. This information may help you make smarter investment decisions.
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.